A.W.S. Ritchie

9.2k total citations
80 papers, 1.9k citations indexed

About

A.W.S. Ritchie is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Surgery. According to data from OpenAlex, A.W.S. Ritchie has authored 80 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Pulmonary and Respiratory Medicine, 18 papers in Cancer Research and 16 papers in Surgery. Recurrent topics in A.W.S. Ritchie's work include Prostate Cancer Treatment and Research (22 papers), Renal cell carcinoma treatment (15 papers) and Prostate Cancer Diagnosis and Treatment (14 papers). A.W.S. Ritchie is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Renal cell carcinoma treatment (15 papers) and Prostate Cancer Diagnosis and Treatment (14 papers). A.W.S. Ritchie collaborates with scholars based in United Kingdom, Switzerland and United States. A.W.S. Ritchie's co-authors include K. James, G. D. CHISHOLM, G. D. Chisholm, H. S. Micklem, Malcolm D. Mason, Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, David P. Dearnaley and John M. Russell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

A.W.S. Ritchie

79 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A.W.S. Ritchie United Kingdom 22 960 426 337 317 296 80 1.9k
Patrick Guinan United States 24 1.4k 1.4× 732 1.7× 314 0.9× 577 1.8× 1.0k 3.4× 214 2.7k
Yeong Jin Choi South Korea 33 661 0.7× 783 1.8× 421 1.2× 345 1.1× 691 2.3× 148 2.9k
George H. Barrows United States 20 613 0.6× 296 0.7× 199 0.6× 630 2.0× 399 1.3× 40 1.9k
Kathleen C. Torkko United States 29 916 1.0× 290 0.7× 517 1.5× 900 2.8× 661 2.2× 46 2.6k
Gregor Mikuz Austria 29 1.1k 1.1× 948 2.2× 123 0.4× 504 1.6× 628 2.1× 116 2.6k
Francesco Paolo Selvaggi Italy 27 1.0k 1.1× 589 1.4× 181 0.5× 259 0.8× 625 2.1× 83 2.5k
Shingo Hatakeyama Japan 26 842 0.9× 675 1.6× 418 1.2× 473 1.5× 961 3.2× 188 2.6k
Jörg Fuchs Germany 27 837 0.9× 953 2.2× 257 0.8× 518 1.6× 660 2.2× 171 3.0k
Jonathan Myles United States 25 706 0.7× 564 1.3× 83 0.2× 460 1.5× 625 2.1× 76 2.3k
Lutz Trojan Germany 27 1.9k 2.0× 662 1.6× 299 0.9× 537 1.7× 1.0k 3.5× 129 3.4k

Countries citing papers authored by A.W.S. Ritchie

Since Specialization
Citations

This map shows the geographic impact of A.W.S. Ritchie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A.W.S. Ritchie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A.W.S. Ritchie more than expected).

Fields of papers citing papers by A.W.S. Ritchie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A.W.S. Ritchie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A.W.S. Ritchie. The network helps show where A.W.S. Ritchie may publish in the future.

Co-authorship network of co-authors of A.W.S. Ritchie

This figure shows the co-authorship network connecting the top 25 collaborators of A.W.S. Ritchie. A scholar is included among the top collaborators of A.W.S. Ritchie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A.W.S. Ritchie. A.W.S. Ritchie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
3.
Blinman, Prunella, Andrew Martin, Shomik Sengupta, et al.. (2017). Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?. Annals of Oncology. 29(2). 370–376. 12 indexed citations
4.
5.
James, Nicholas D., Johann S. de Bono, Melissa Spears, et al.. (2017). Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476).. Journal of Clinical Oncology. 35(15_suppl). LBA5003–LBA5003. 3 indexed citations
6.
Sydes, Matthew R., Mahesh Parmar, Malcolm D. Mason, et al.. (2012). Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials. 13(1). 168–168. 100 indexed citations
7.
Sydes, Matthew R., Nicholas D. James, Malcolm D. Mason, et al.. (2011). Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials. 12(S1). 8 indexed citations
8.
Belldegrun, Arie S., et al.. (2002). Renal and adrenal tumors : biology and management. Oxford University Press eBooks. 13 indexed citations
9.
Okoye, Bruce, et al.. (1995). Transvesical endoscopic drainage of a seminal vesicle cyst. British Journal of Urology. 76(6). 810–810. 17 indexed citations
10.
Parr, Nick, A.W.S. Ritchie, Gordon Smith, & David A. Tolley. (1992). J‐wire Facilitates Retrograde Manipulation of Ureteric Calculi Prior to Extracorporeal Shock Wave Lithotripsy. British Journal of Urology. 69(6). 568–570. 1 indexed citations
11.
Parr, Nick, A.W.S. Ritchie, Sami A. Moussa, & David A. Tolley. (1991). The Impact of Extracorporeal Piezoelectric Lithotripsy on the Management of Ureteric Calculi: an Audit. British Journal of Urology. 67(1). 18–23. 11 indexed citations
12.
Ritchie, A.W.S., Nick Parr, Sami A. Moussa, & David A. Tolley. (1990). Lithotripsy for Calculi in Caliceal Diverticula?. British Journal of Urology. 66(1). 6–8. 33 indexed citations
13.
Ritchie, A.W.S., et al.. (1990). Measures of mortality in prostatic cancer. British Journal of Cancer. 61(3). 465–468. 10 indexed citations
14.
deKernion, Jean B., Eliahu Mukamel, A.W.S. Ritchie, et al.. (1989). Prognostic significance of the DNA content of renal carcinoma. Cancer. 64(8). 1669–1673. 30 indexed citations
15.
Ritchie, A.W.S., et al.. (1988). The Significance of Atypia in Fine Needle Aspiration Cytology of the Prostate. The Journal of Urology. 140(4). 761–764. 10 indexed citations
16.
Ritchie, A.W.S., K. James, H. S. Micklem, & G. D. CHISHOLM. (1984). Lymphocyte Subsets in Renal Carcinoma—a Sequential Study Using Monoclonal Antibodies. British Journal of Urology. 56(2). 140–148. 14 indexed citations
17.
Ritchie, A.W.S., K. James, & G. D. CHISHOLM. (1984). The effect of anaesthesia and surgery for benign disease of the upper urinary tract on circulating leucocyte subpopulations identified with monoclonal antibodies. Urological Research. 12(6). 267–269. 5 indexed citations
18.
Ritchie, A.W.S., Isabelle P. Oswald, H. S. Micklem, et al.. (1983). Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies.. BMJ. 286(6380). 1773–1775. 162 indexed citations
19.
Ritchie, A.W.S. & G. D. Chisholm. (1983). The natural history of renal carcinoma.. PubMed. 10(4). 390–400. 132 indexed citations
20.
Archer, G. T. L., et al.. (1952). Studies on Urinary Carriage of Enteric Group Organisms. Journal of the Royal Army Medical Corps. 98(3). 189–197. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026